Drugs / LY4170156
LY4170156
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06400472 | May 2024 → Feb 2027 expected | colorectal neoplasm, endometrium neoplasm, non-small cell lung carcinoma, ovarian neoplasm +3 | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07213804 | Oct 2025 → Nov 2028 expected | fallopian tube neoplasm, metastatic neoplasm, ovarian neoplasm, peritoneal neoplasm | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4170156 | “Sofetabart Mipitecan (LY4170156)” NCT07213804 ↗ |
| Known as | Sofe-M | “Sofetabart Mipitecan (Sofe-M)” NCT07213804 ↗ |
| Known as | Sofetabart Mipitecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07213804 ↗ |
| Route | Intravenous | “Escalating doses of LY4170156 administered intravenously (IV)” NCT06400472 ↗ |